What is Medrhythms?
Medrhythms is dedicated to developing next-generation neurotherapeutics to improve brain health and assist individuals dealing with neurologic injuries and walking disabilities. Their proprietary technology platform leverages Rhythmic Auditory Stimulation (RAS), combining music, sensors, and software to enhance mobility and functional outcomes for patients with conditions such as stroke and Parkinson's disease. The company aims to transform patient care by providing digital therapeutics through an extensive and culturally rich music library, personalized for each user. Medrhythms is committed to reclaiming independence and enhancing the quality of life for millions affected by neurologic gait disorders worldwide. This focus on digital therapeutics for gait disorders positions them as a key player in the evolving landscape of neurological rehabilitation.
How much funding has Medrhythms raised?
Medrhythms has raised a total of $35.6M across 3 funding rounds:
Series A
$5.3M
Series B
$27M
Private Equity
$3.3M
Series A (2018): $5.3M with participation from Jean Hoffman and Peter J. Werth
Series B (2021): $27M led by Morningside Venture Capital, Global Brain, Advantage Capital, Werth Family Investment Associates, and Bose Ventures
Private Equity (2026): $3.3M, investors not publicly disclosed
Key Investors in Medrhythms
Morningside Venture Capital
Morningside Venture Capital is a private equity and venture capital firm specializing in early-stage technology company investments.
Global Brain
Global Brain is an independent venture capital firm that specializes in supporting startups to achieve global success through hands-on assistance and collaboration with large corporations.
Advantage Capital
Advantage Capital Partners operates as a venture capital firm, investing in cleantech, communication, energy, information technology, and life sciences industries.
What's next for Medrhythms?
The recent major strategic investment signifies a pivotal moment for Medrhythms, likely enabling the company to accelerate its product development pipeline, expand its market reach, and further validate its Rhythmic Auditory Stimulation (RAS) platform. This capital infusion is expected to fuel clinical trials, enhance the digital therapeutic platform's features, and potentially support broader commercialization efforts. As Medrhythms continues to grow, its focus will likely remain on demonstrating the efficacy of its music-based neurotherapeutics in improving patient outcomes for a range of neurological conditions, solidifying its position in the digital health and neurorehabilitation sectors.
See full Medrhythms company page
